New Speaker Confirmed for P2T 2012 - Dr Allan Robins

Allan Robins, Ph.D. was appointed ViaCyte's Acting Chief Executive Officer in July 2011 and concurrently serves as Vice President and Chief Technical Officer. Prior to ViaCyte, Dr. Robins served as Chief Scientific Officer at BresaGen, Inc. and under his leadership, BresaGen, Inc. was awarded significant support for its stem cell research from the National Institutes of Health. Prior to BresaGen, Inc., Dr. Robins was Chief Scientific Officer at BresaGen Limited, where he helped raise over $30 million and developed a proprietary expression system which continues to be used in the production of protein pharmaceuticals.

Dr Robins’ P2T 2012 presentation will be titled ES Derived Islets to Treat Type I Diabetes

Confirmed Speakers

We are pleased to announce the following speakers have confirmed for Progress to Therapy 2012:

• Andrew Baker (University of Glasgow
• Colin Berry (University of Glasgow)
• Chris Breuer (Yale, USA)
• Robert Deans (Athersys, USA)
• Chris Denning (Nottingham)
• Joyce Frey (Pharmanet, USA)
• Timothy Kieffer (Diabetes Research, Vancouver)
• Nick Mills (University of Edinburgh)
• Bruno Peault (University of Edinburgh)
• Paul Riley (Oxford) 
• Jozef Bartunek (Eindhoven University, Holland)

• Costanza Emaneuli (University of Bristol)

• Steve Duncan (Medical College of Wisconsin, USA)

• Molly Stevens (Imperial College London)

• Allan Robbins (Viacyte Inc)

Find out more about the speakers here.